Studieoverzicht

Study name: REGN7075: COMBINE-EGFR-1 (COstiM BIspecifics for the treatment of NEoplasia)

Histology	NSCLC, all subtypes, Other
Tumor stage	Stage III - IV
Host / recruiting site 1	Erasmus MC	Enrollment	Recruiting
Host / recruiting site 2	Antoni van Leeuwenhoek	Enrollment	Recruiting
Therapy line	Later line (≥2L)
Design	A PHASE 1/2 STUDY OF REGN7075 (EGFRxCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS. Cohort G: EGFR-mutant NSCLC post third generation tyrosine kinase inhibitor (TKI).
Intervention	REGN7075 (EGFRxCD28 COSTIMULATORY BISPECIFIC ANTIBODY) +/- Cemiplimab
Key inclusion criteria	Cohort G: EGFR-Mutant NSCLC Post 3rd Generation TKI Have previously documented targetable EGFR mutations: EGFR Exon 19 deletion, EGFR L858R mutation, activating EGFR Exon 20 insertion, Exon 18/21 atypical mutations Stable CNS disease allowed
Key exclusion criteria	Small cell transformation is excluded Prior chemotherapy or anti-PD-1/PD-L1 therapy
Contact information	Log in voor de contactinformatie